Phase I, Phase I

A Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

Volunteers
Health Professionals

What is the purpose of this trial?

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care. The study will last up to approximately 2 years.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Ingrid Palma

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

So Yeon Kim, MD
Assistant Professor

Sub-Investigators

Last Updated
08/06/2024
Study HIC
#2000031441